Tamara Leclercq

712 total citations
14 papers, 562 citations indexed

About

Tamara Leclercq is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Tamara Leclercq has authored 14 papers receiving a total of 562 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 6 papers in Molecular Biology and 6 papers in Genetics. Recurrent topics in Tamara Leclercq's work include Chronic Myeloid Leukemia Treatments (8 papers), Sphingolipid Metabolism and Signaling (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Tamara Leclercq is often cited by papers focused on Chronic Myeloid Leukemia Treatments (8 papers), Sphingolipid Metabolism and Signaling (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Tamara Leclercq collaborates with scholars based in Australia, United Kingdom and United States. Tamara Leclercq's co-authors include Stuart M. Pitson, Paul A.B. Moretti, Mathew A. Vadas, Julia R. Zebol, Pu Xia, Binks W. Wattenberg, Francesca Tonelli, Keng Gat Lim, Nigel J. Pyne and Evgeny Berdyshev and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Experimental Medicine and Blood.

In The Last Decade

Tamara Leclercq

14 papers receiving 558 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tamara Leclercq Australia	8	492	265	56	55	50	14	562
Rachel S. Salamon United States	9	317 0.6×	69 0.3×	34 0.6×	66 1.2×	21 0.4×	10	436
Ayman Mahdy United States	5	359 0.7×	115 0.4×	73 1.3×	43 0.8×	9 0.2×	6	417
Jeannene Butler United States	6	291 0.6×	117 0.4×	30 0.5×	29 0.5×	72 1.4×	8	417
Nagisa Sakurai United States	11	301 0.6×	117 0.4×	22 0.4×	69 1.3×	31 0.6×	13	412
Angen Liu United States	6	422 0.9×	87 0.3×	35 0.6×	71 1.3×	13 0.3×	6	515
Katherine E. Ward United States	8	389 0.8×	68 0.3×	39 0.7×	59 1.1×	15 0.3×	9	441
Fabien Zassadowski France	9	270 0.5×	59 0.2×	20 0.4×	36 0.7×	140 2.8×	11	372
Jennifer S. Carew United States	3	283 0.6×	194 0.7×	11 0.2×	45 0.8×	38 0.8×	4	412
Stefan Welti Germany	7	270 0.5×	173 0.7×	30 0.5×	23 0.4×	9 0.2×	9	437
Saubhik Sengupta United States	7	326 0.7×	106 0.4×	28 0.5×	73 1.3×	10 0.2×	7	430

Countries citing papers authored by Tamara Leclercq

Since Specialization

Citations

This map shows the geographic impact of Tamara Leclercq's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tamara Leclercq with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tamara Leclercq more than expected).

Fields of papers citing papers by Tamara Leclercq

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tamara Leclercq. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tamara Leclercq. The network helps show where Tamara Leclercq may publish in the future.

Co-authorship network of co-authors of Tamara Leclercq

This figure shows the co-authorship network connecting the top 25 collaborators of Tamara Leclercq. A scholar is included among the top collaborators of Tamara Leclercq based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tamara Leclercq. Tamara Leclercq is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Heatley, Susan L., Tamara Leclercq, Barbara J. McClure, et al.. (2021). In-vitromodeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion geneRANBP2-ABL1- implications for targeted therapy. Leukemia & lymphoma. 62(5). 1157–1166. 3 indexed citations

Kok, Chung Hoow, David T Yeung, Lu Liu, et al.. (2019). Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Advances. 3(10). 1610–1621. 23 indexed citations

Ranasinghe, Damith C., David L. Adelson, Tamara Leclercq, et al.. (2017). Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia. PLoS ONE. 12(1). e0168947–e0168947. 6 indexed citations

Kok, Chung Hoow, Verity A Saunders, Jarrad M. Goyne, et al.. (2017). Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells. Haematologica. 102(5). 843–853. 11 indexed citations

Heatley, Susan L., Teresa Sadras, Tamara Leclercq, et al.. (2016). In Vitro Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance - Implications for Targeted Therapy. Blood. 128(22). 3957–3957. 3 indexed citations

Neubauer, Heidi A., Duyen Pham, Julia R. Zebol, et al.. (2016). An oncogenic role for sphingosine kinase 2. Oncotarget. 7(40). 64886–64899. 51 indexed citations

Kok, Chung Hoow, et al.. (2015). A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib. Blood. 126(23). 596–596. 1 indexed citations

Eadie, Laura N, Verity A Saunders, Tamara Leclercq, et al.. (2015). The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2. Blood. 126(23). 4841–4841. 2 indexed citations

Liu, Lu, Verity A Saunders, Chung Hoow Kok, et al.. (2014). Modeling Ponatinib Resistance in BCR-ABL1+ Cell Lines: Implications for Ponatinib Resistance in TKI-Resistant and TKI-naïve Patients. Blood. 124(21). 4515–4515. 1 indexed citations

10.

Lim, Keng Gat, Francesca Tonelli, Evgeny Berdyshev, et al.. (2012). Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: Functional differences between sphingosine kinase 1a and 1b. The International Journal of Biochemistry & Cell Biology. 44(9). 1457–1464. 34 indexed citations

11.

Loveridge, Carolyn J., Francesca Tonelli, Tamara Leclercq, et al.. (2010). The Sphingosine Kinase 1 Inhibitor 2-(p-Hydroxyanilino)-4-(p-chlorophenyl)thiazole Induces Proteasomal Degradation of Sphingosine Kinase 1 in Mammalian Cells. Journal of Biological Chemistry. 285(50). 38841–38852. 103 indexed citations

12.

Leclercq, Tamara, Paul A.B. Moretti, Mathew A. Vadas, & Stuart M. Pitson. (2008). Eukaryotic Elongation Factor 1A Interacts with Sphingosine Kinase and Directly Enhances Its Catalytic Activity. Journal of Biological Chemistry. 283(15). 9606–9614. 45 indexed citations

13.

Leclercq, Tamara & Stuart M. Pitson. (2006). Cellular signalling by sphingosine kinase and sphingosine 1‐phosphate. IUBMB Life. 58(8). 467–472. 49 indexed citations

14.

Pitson, Stuart M., Pu Xia, Tamara Leclercq, et al.. (2004). Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. The Journal of Experimental Medicine. 201(1). 49–54. 230 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact